It has been reported that the absence of ARMCX1 enhances the regeneration of hematopoietic stem cells (Holmfeldt et al., 2016) and may thus regulate leukemia, myelodysplastic syndrome (MDS), metastatic cancer, and autoimmune diseases (AIDs) (Calvi and Link, 2015; Swart et al., 2017). Here, ARMCX1 is linked to metastatic malignant neoplasm.